Engineering mesenchymal stem cells: a novel therapeutic approach in breast cancer

Heidari, Razieh; Dehkordi, Neda Gholamian; Mohseni, Roohollah; Safaei, Mohsen

doi:10.1080/1061186x.2020.1775842

Cited by 12 publications

(9 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 The MSCs and their cellular vehicles have been increasingly recognized as novel promising therapeutic options for BC treatment. 21 In this paper, we identified an important function of adMSC-Exos in the reduction of DDP resistance of BC MCF-7 and MDA-MB-23 cells with the crucial involvement of miR-1236 as well as the suppression of SLC9A1 and the Wnt/β-catenin axis.…”

Section: Discussionmentioning

confidence: 90%

<p>Adipose Mesenchymal Stem Cell-Derived Exosomal microRNA-1236 Reduces Resistance of Breast Cancer Cells to Cisplatin by Suppressing SLC9A1 and the Wnt/β-Catenin Signaling</p>

Jia¹,

Zhu²,

Sun³

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Emerging evidence has noted the versatile functions of mesenchymal stem cell-derived exosomes (MSC-Exos) in cancer control. This work aims to probe to function of adipose MSC-Exos (adMSC-Exos) in drug-resistance of breast cancer (BC) cells to cisplatin (DDP) and the molecules involved. Methods: Parental and DDP-resistant BC cell lines MCF-7 and MDA-MB-231 were used. All cells were pre-treated with adMSC-Exos. Then, the viability and apoptosis of cells after DDP treatment were determined. Differentially expressed miRNAs after adMSC-exo treatment were screened out. Rescue experiments were conducted by pre-transfecting miR-1236 inhibitor into adMSCs, and the role of miR-1236 in DDP sensitivity was determined. Targeting mRNAs of miR-1236 were predicted by bioinformatics analysis. Altered SLC9A1 expression was administrated to evaluate its function in DDP resistance. Results: The adMSC-Exos notably increased the sensitivity of either parental or DDPresistant BC cells to DDP. SLC9A1 was notably highly expressed in DDP-resistant cells but inhibited following adMSC-exo administration. Importantly, miR-1236, which could directly bind to SLC9A1 and suppress its expression, was confirmed as an enriched miRNA in adMSC-Exos. Either inhibition of miR-1236 or upregulation of SLC9A1 blocked the pro-sensitize roles of adMSC-Exos. In addition, the Wnt/β-catenin pathway activity was suppressed by adMSC-Exos but recovered by SLC9A1. Conclusion: This study evidenced that adMSC-Exos carry miR-1236 to increase sensitivity of BC cells to DDP with the involvement of SLC9A1 downregulation and Wnt/β-catenin inactivation. This finding may offer novel insights into treatment for drug-resistant BC.

show abstract

Section: Discussionmentioning

confidence: 90%

<p>Adipose Mesenchymal Stem Cell-Derived Exosomal microRNA-1236 Reduces Resistance of Breast Cancer Cells to Cisplatin by Suppressing SLC9A1 and the Wnt/β-Catenin Signaling</p>

Jia¹,

Zhu²,

Sun³

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…Nevertheless, it has to be taken into account that some authors reported some bone marrow-mesenchymal stromal/stem cells anti-tumoural functions, such as tumour growth suppression and reduction of the size of metastases (Kostadinova & Mourdjeva, 2020). Therefore, bone marrow-mesenchymal stromal/stem cells can be considered as unique candidates for the development of anti-cancer therapies, either by their usage as regulators of the tumour microenvironment or as cell vehicles for drug delivery (Heidari et al, 2020;Liu et al, 2022;Mohr & Zwacka, 2018). Some of the sources of human mesenchymal stromal/stem cells for experimental and clinical uses are bone marrow, adipose tissue, umbilical cord, Wharton's Jelly and placenta.…”

Section: Mesenchymal Stromal/stem Cellsmentioning

confidence: 99%

“…On the other hand, the stimulation of TLR3 promotes a mesenchymal stem cell 2 phenotype, with the secretion of immunosuppressive mediators like PGE 2 , indoleamine‐2,3‐dioxygenase and IL‐10 (De Witte et al, 2016; Meisel et al, 2004). These characteristics indicate that mesenchymal stem cell 1 and 2 may have anti‐ and pro‐tumorigenic properties, respectively (Heidari et al, 2020).…”

Section: Mesenchymal Stromal/stem Cellsmentioning

confidence: 99%

Mesenchymal stem cells and cancer‐associated fibroblasts as a therapeutic strategy for breast cancer

Borzone

Giorello

Sanmartin

et al. 2022

British J Pharmacology

View full text Add to dashboard Cite

Breast cancer is the most common type of cancer and the leading cause of death among women. Recent evidence suggests that mesenchymal stromal/stem cells and cancer‐associated fibroblasts (CAFs) have an essential role in cancer progression, invasion and therapy resistance. Therefore, they are considered as highly promising future therapeutic targets against breast cancer. The intrinsic tumour tropism and immunomodulatory capacities of mesenchymal stromal/stem cells are of special relevance for developing mesenchymal stromal/stem cells‐based anti‐tumour therapies that suppress primary tumour growth and metastasis. In addition, the utilization of therapies that target the stromal components of the tumour microenvironment in combination with standard drugs is an innovative tool that could improve patients’ response to therapies and their survival. In this review, we discuss the currently available information regarding the possible use of mesenchymal stromal/stem cells‐derived anti‐tumour therapies, as well as the utilization of therapies that target CAFs in breast cancer microenvironment. Finally, these data can serve as a guide map for future research in this field, ultimately aiding the effective transition of these results into the clinic.

show abstract

“…Mesenchymal stem cells (MSCs) have become a promising therapeutic agent for targeting BCSCs in the cell targeted therapy of breast cancer (141). MSCs have the characteristics of multi-differentiation potential, low immunogenicity, and homing to tumor tissues.…”

Section: Cell Targeted Therapymentioning

confidence: 99%

New Advances in Targeted Therapy of HER2-Negative Breast Cancer

Peng

Xie

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer has an extremely high incidence in women, and its morbidity and mortality rank first among female tumors. With the increasing development of molecular biology and genomics, molecular targeted therapy has become one of the most active areas in breast cancer treatment research and has also achieved remarkable achievements. However, molecular targeted therapy is mainly aimed at HER2-positive breast cancer and has not yet achieved satisfactory curative effect on HER2-negative breast cancer. This article describes the potential targets that may be used for breast cancer treatment from the aspects of PI3K/AKT signaling pathway, DDR, angiogenesis, the cell cycle, breast cancer stem cells, etc., and explores possible inhibitors for the treatment of HER2-negative breast cancer, such as PI3K inhibitors, AKT inhibitors and m-TOR inhibitors that inhibit the PI3K/AKT signaling pathway, small molecule tyrosine kinase inhibitors that restrain angiogenesis, CDK inhibitors, aurora kinase inhibitors and HDAC inhibitors that block cell cycle, as well as the drugs targeting breast cancer stem cells which have been a hit, aiming to provide a new idea and strategy for the treatment of HER2-negative breast cancer.

show abstract

Engineering mesenchymal stem cells: a novel therapeutic approach in breast cancer

Cited by 12 publications

References 75 publications

<p>Adipose Mesenchymal Stem Cell-Derived Exosomal microRNA-1236 Reduces Resistance of Breast Cancer Cells to Cisplatin by Suppressing SLC9A1 and the Wnt/β-Catenin Signaling</p>

<p>Adipose Mesenchymal Stem Cell-Derived Exosomal microRNA-1236 Reduces Resistance of Breast Cancer Cells to Cisplatin by Suppressing SLC9A1 and the Wnt/β-Catenin Signaling</p>

Mesenchymal stem cells and cancer‐associated fibroblasts as a therapeutic strategy for breast cancer

New Advances in Targeted Therapy of HER2-Negative Breast Cancer

Contact Info

Product

Resources

About